Kymera Therapeutics (NASDAQ: KYMR) announced it has completed enrollment in its BROADEN2 Phase 2b clinical trial of KT-621 for moderate ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE